ENOrphanet Journal of Rare Diseases | Six-minute walk distance predicts mortality risk in lymphangioleiomyomatosis patients
Date: February 09, 2026
Classification: Frontiers
Recommend:
Based on a cohort of 403 LAM patients, this study determined the optimal prognostic cutoff value for six-minute walk distance (6MWD) as 425.5 meters and confirmed its independent value in predicting mortality risk, providing a simple and effective method for clinical assessment.
Literature Overview
The article titled 'Six-minute walk distance predicting the risk of mortality in lymphangioleiomyomatosis patients,' published in the Orphanet Journal of Rare Diseases, reviews and summarizes the value of the six-minute walk test (6MWT) in assessing disease severity and prognosis in patients with lymphangioleiomyomatosis (LAM). By retrospectively analyzing clinical data from 403 patients in the Peking Union Medical College Hospital LAM registry cohort, the study constructed survival and disease progression datasets to systematically evaluate the relationship between 6MWT parameters and lung function, quality of life, and survival outcomes. The study found that 6MWD was significantly correlated with baseline FEV1%pred, and that 6MWD < 425.5 m was an independent risk factor for death or lung transplantation. This research provides a simple, safe, and prognostically valuable clinical assessment tool for LAM patients, helping to optimize individualized management strategies. It also explores the potential application of 6MWT in patients unable to complete pulmonary function testing, thereby expanding its applicability in rare respiratory diseases.Background Knowledge
Lymphangioleiomyomatosis (LAM) is a rare, low-grade malignant neoplastic disease primarily affecting women of reproductive age. It has two subtypes: sporadic LAM and tuberous sclerosis complex-associated LAM, both caused by mutations in the TSC1/TSC2 genes leading to aberrant activation of the mTOR signaling pathway, resulting in diffuse cystic lung lesions. As the disease progresses, patients develop progressive dyspnea, pneumothorax, chylothorax, and other complications, potentially culminating in respiratory failure. Currently, pulmonary function indicators such as FEV1%pred are the primary basis for assessing disease severity and determining whether to initiate mTOR inhibitors (e.g., sirolimus). However, pulmonary function testing is limited by equipment availability, patient cooperation, and contraindications (e.g., pneumothorax). The six-minute walk test (6MWT), as a simple, non-invasive, and repeatable comprehensive functional assessment method, has been proven to have good prognostic predictive value in various respiratory diseases such as chronic obstructive pulmonary disease and pulmonary arterial hypertension. Although previous studies suggest that 6MWT may reflect disease status in LAM patients, its ability to predict mortality risk and the optimal cutoff value have not been clearly established in large cohorts. Therefore, exploring the clinical value of 6MWT in LAM patients, especially its independent predictive role for survival, has significant practical implications and clinical translation potential.
Research Methods and Experiments
This study is a single-center retrospective cohort study that included 403 confirmed LAM patients from the Peking Union Medical College Hospital LAM registry to construct survival and disease progression datasets. The survival dataset included all patients who completed baseline assessments, with follow-up endpoints being death, lung transplantation, loss to follow-up, or December 31, 2019. The disease progression dataset required patients to have at least two pulmonary function tests at least three months apart. Baseline assessments included clinical data, pulmonary function tests (PFTs), high-resolution CT, serum VEGF-D levels, six-minute walk test (6MWT), and the St. George's Respiratory Questionnaire (SGRQ). The 6MWT was performed strictly according to the American Thoracic Society (ATS) guidelines, recording the six-minute walk distance (6MWD), oxygen saturation (SpO₂) before and after walking, exercise-induced desaturation, and Borg dyspnea score. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal 6MWD cutoff value for predicting mortality risk. Kaplan-Meier method was used to plot survival curves, and multivariable Cox regression analysis was performed to identify independent prognostic factors. Additionally, mixed-effects models were used to calculate the annual decline rate of FEV1 and analyze the relationship between 6MWT parameters and disease progression.Key Conclusions and Findings
Research Significance and Outlook
This study provides high-level evidence for the use of 6MWT in the management of LAM patients, establishing 425.5 meters as a practical cutoff value for predicting mortality risk. This finding makes 6MWT a simple, cost-effective, and prognostically valuable clinical tool, especially suitable for patients unable to tolerate or contraindicated for pulmonary function testing. Incorporating 6MWT parameters enhances the comprehensiveness of clinical assessment, helping to identify high-risk patients earlier and intervene promptly. Additionally, the study suggests that 6MWT reflects systemic functional status rather than merely the rate of lung function decline, offering a new perspective on understanding the systemic impact of LAM.
Future research could further explore the relationship between longitudinal changes in 6MWT parameters and treatment response, quality of life, and hard endpoints, establishing dynamic risk assessment models. Meanwhile, multicenter prospective studies should be conducted to validate the generalizability of this cutoff value and explore integrated prediction models combining radiomics, biomarkers, and 6MWT to achieve more precise risk stratification and personalized treatment strategies.
Conclusion
This study systematically evaluated the clinical value of the six-minute walk test (6MWT) in patients with lymphangioleiomyomatosis (LAM), establishing a prognostic cutoff value of 425.5 meters for six-minute walk distance (6MWD) based on a retrospective cohort analysis of 403 patients. The study found that 6MWD was significantly associated with baseline lung function (FEV1%pred, DLCO%pred), oxygen saturation, dyspnea symptoms, and quality-of-life scores, and that 6MWD < 425.5 m was an independent risk factor for death or lung transplantation, with predictive value independent of FEV1%pred and sirolimus treatment status. Although 6MWT parameters failed to predict the annual decline rate of lung function, their ability to comprehensively reflect overall cardiopulmonary function makes them an important prognostic assessment tool. This study emphasizes the practicality of 6MWT in LAM clinical management, particularly providing a feasible alternative for patients unable to complete pulmonary function testing. Integrating 6MWT results can help clinicians more comprehensively assess patient status, optimize risk stratification, and support individualized treatment decisions. Future validation of this cutoff value in larger, multicenter cohorts is needed, along with exploration of its potential in treatment monitoring and dynamic risk assessment.
